Patents by Inventor Max S. Wicha

Max S. Wicha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140011274
    Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise to both more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.
    Type: Application
    Filed: December 14, 2012
    Publication date: January 9, 2014
    Applicant: The Regents of the University of Michigan
    Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
  • Publication number: 20130142785
    Abstract: The present invention relates to compositions, methods, and kits for treating cancers with HER2 targeting agents and preventing resistance thereto. In particular embodiments, non-HER2-amplified cancers are treated with HER2 targeting agents, wherein the cancer stem cells in the cancer express HER2 and/or HER2 indicator marker. The present invention also relates to compositions, methods, and kits for detecting expression of HER2 and/or a HER2 indicator marker in non-HER2-amplified cancer samples from a subject, and identifying the subject as responsive to treatment with a HER2 targeting agent and/or treating the subject with a HER2 targeting agent.
    Type: Application
    Filed: October 25, 2012
    Publication date: June 6, 2013
    Inventors: Max S. Wicha, Hasan Korkaya
  • Patent number: 8435746
    Abstract: The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides a novel stem cell cancer marker, ALDH1, useful for the diagnosis, characterization, and treatment of solid tumor stem cells.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: May 7, 2013
    Assignee: The Regents of the University of Michigan
    Inventors: Max S. Wicha, Gabriela Dontu, Christophe Ginestier, Emmanuelle Charafe-Jauffret, Suling Liu
  • Patent number: 8357491
    Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise to both more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: January 22, 2013
    Assignee: The Regents of the University of Michigan
    Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
  • Publication number: 20120295350
    Abstract: The invention provides methods for treating cancer via administering to a patient having a solid tumor a therapeutically effective amount of an antibody against Delta-like ligand 4(D114) or other Notch pathway components. The solid tumor may comprise solid tumor stem cells.
    Type: Application
    Filed: August 1, 2012
    Publication date: November 22, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Michael F. Clarke, Max S. Wicha, Muhammad Al-Hajj
  • Publication number: 20110092378
    Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise to both more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.
    Type: Application
    Filed: December 28, 2010
    Publication date: April 21, 2011
    Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
  • Publication number: 20110033481
    Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary glad of severely immunodeficient mice. These xenograft assays have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.
    Type: Application
    Filed: April 12, 2010
    Publication date: February 10, 2011
    Inventors: MICHAEL F. CLARKE, MAX S. WICHA, MUHAMMAD AL-HAJJ
  • Patent number: 7850961
    Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: December 14, 2010
    Assignee: The Regents of The University of Michigan
    Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
  • Publication number: 20100291581
    Abstract: The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides a novel stem cell cancer marker, ALDH1, useful for the diagnosis, characterization, and treatment of solid tumor stem cells.
    Type: Application
    Filed: July 6, 2010
    Publication date: November 18, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Max S. Wicha, Gabriela Dontu, Christophe Ginestier, Emmanuelle Charafe-Jauffret, Suling Liu
  • Patent number: 7754206
    Abstract: The invention provides methods for treating cancer via administering to a patient having a solid tumor a therapeutically effective amount of an antibody against Delta-like ligand 4 (D114). The solid tumor may comprise solid tumor stem cells.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: July 13, 2010
    Assignee: The Regents of the University of Michigan
    Inventors: Michael F. Clarke, Max S. Wicha, Muhammad Al-Hajj
  • Publication number: 20100136031
    Abstract: The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).
    Type: Application
    Filed: November 11, 2009
    Publication date: June 3, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Max S. Wicha, Christophe Ginestier
  • Patent number: 7713710
    Abstract: A small percentage of cells within an established tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. The solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: May 11, 2010
    Assignee: The Regents of the University of Michigan
    Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
  • Publication number: 20090004205
    Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.
    Type: Application
    Filed: January 9, 2007
    Publication date: January 1, 2009
    Inventors: Michael F. Clarke, Max S. Wicha, Muhammad Al-Hajj
  • Publication number: 20080261244
    Abstract: The present invention relates to the field of oncology and provides novel compositions and methods for diagnosing and treating pancreatic cancer. In particular, the present invention provides pancreatic cancer stem cells useful for the study, diagnosis, and treatment of solid tumors.
    Type: Application
    Filed: January 24, 2008
    Publication date: October 23, 2008
    Applicant: The Regents of the University of Michigan
    Inventors: Max S. Wicha, Diane M. Simeone, Michael F. Clarke
  • Publication number: 20080194022
    Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.
    Type: Application
    Filed: April 20, 2007
    Publication date: August 14, 2008
    Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
  • Publication number: 20080187938
    Abstract: The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides a novel stem cell cancer marker, ALDH1, useful for the diagnosis, characterization, and treatment of solid tumor stem cells.
    Type: Application
    Filed: September 24, 2007
    Publication date: August 7, 2008
    Applicant: The Regents of the University of Michigan
    Inventors: Max S. Wicha, Gabriela Dontu, Christophe Ginestier, Emmanuelle Charafe-Jauffret, Suling Liu
  • Patent number: 7115360
    Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell.
    Type: Grant
    Filed: August 2, 2001
    Date of Patent: October 3, 2006
    Assignee: Regents of the University of Michigan
    Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad al-Hajj
  • Patent number: 6984522
    Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. The solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: January 10, 2006
    Assignee: Regents of the University of Michigan
    Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
  • Publication number: 20040037815
    Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.
    Type: Application
    Filed: August 25, 2003
    Publication date: February 26, 2004
    Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
  • Publication number: 20020119565
    Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.
    Type: Application
    Filed: August 1, 2001
    Publication date: August 29, 2002
    Applicant: Regents of the University of Michigan
    Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj